Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab in Lung Cancer Treatment
Trendline

Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab in Lung Cancer Treatment

What's Happening? Summit Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for ivonescimab. The application sought approval for ivonescimab in combination with platinum-containing
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.